JP2024514703A5 - - Google Patents

Info

Publication number
JP2024514703A5
JP2024514703A5 JP2023564639A JP2023564639A JP2024514703A5 JP 2024514703 A5 JP2024514703 A5 JP 2024514703A5 JP 2023564639 A JP2023564639 A JP 2023564639A JP 2023564639 A JP2023564639 A JP 2023564639A JP 2024514703 A5 JP2024514703 A5 JP 2024514703A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
fluoroalkyl
general formula
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/087652 external-priority patent/WO2022222921A1/zh
Publication of JP2024514703A publication Critical patent/JP2024514703A/ja
Publication of JP2024514703A5 publication Critical patent/JP2024514703A5/ja
Pending legal-status Critical Current

Links

JP2023564639A 2021-04-22 2022-04-19 ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 Pending JP2024514703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110439238 2021-04-22
CN202110439238.4 2021-04-22
PCT/CN2022/087652 WO2022222921A1 (zh) 2021-04-22 2022-04-19 含哌嗪结构的parp抑制剂、其制备方法及医药用途

Publications (2)

Publication Number Publication Date
JP2024514703A JP2024514703A (ja) 2024-04-02
JP2024514703A5 true JP2024514703A5 (cg-RX-API-DMAC7.html) 2025-04-28

Family

ID=83721971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564639A Pending JP2024514703A (ja) 2021-04-22 2022-04-19 ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用

Country Status (10)

Country Link
US (1) US20240336624A1 (cg-RX-API-DMAC7.html)
EP (1) EP4328224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514703A (cg-RX-API-DMAC7.html)
KR (1) KR20230175225A (cg-RX-API-DMAC7.html)
CN (1) CN117279916B (cg-RX-API-DMAC7.html)
AU (1) AU2022261011A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213029A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012361A (cg-RX-API-DMAC7.html)
WO (1) WO2022222921A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CN116867783B (zh) * 2021-04-23 2026-08-07 康百达(四川)生物医药科技有限公司 吡啶衍生物及其在医药上的应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051812A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
AU2023275808A1 (en) * 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
US20250346573A1 (en) * 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
CN117946074A (zh) * 2022-10-20 2024-04-30 上海海和药物研究开发股份有限公司 具有parp1抑制活性的化合物及其用途
CN120092010A (zh) * 2022-11-02 2025-06-03 轩竹生物科技股份有限公司 多环类聚(adp核糖)聚合酶选择性抑制剂
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
WO2024213111A1 (zh) * 2023-04-14 2024-10-17 微境生物医药科技(上海)有限公司 Parp抑制剂、其制备方法及医药用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053373A1 (en) * 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
EP2415767B1 (en) * 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
PT3562822T (pt) * 2016-12-30 2021-06-02 Mitobridge Inc Inibidores de poli-adp ribose polimerase (parp)
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CN117177972A (zh) * 2021-04-19 2023-12-05 新特拉有限公司 Parp1抑制剂及其用途
CN116710433B (zh) * 2021-04-23 2026-05-05 康百达(四川)生物医药科技有限公司 一种选择性parp1抑制剂及其应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物

Similar Documents

Publication Publication Date Title
PE20230239A1 (es) Derivado de arilamida con actividad antitumoral
JP2022500425A5 (cg-RX-API-DMAC7.html)
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
JP2021513547A5 (cg-RX-API-DMAC7.html)
AR035959A1 (es) Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion
AR013879A1 (es) Compuesto parasiticida derivado pirazol, formulaciones veterinarias o agricolas y composiciones farmaceuticas que lo contienen, el uso de dicho compuesto para la manufactura de medicamentos, compuestos utiles y procedimiento para la fabricacion de dicho compuesto
JP2005505618A5 (cg-RX-API-DMAC7.html)
JP2023552610A5 (cg-RX-API-DMAC7.html)
JP2020505440A5 (cg-RX-API-DMAC7.html)
RU2010107169A (ru) Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого
JP2020503341A5 (cg-RX-API-DMAC7.html)
RU2010115337A (ru) Трициклические гетероциклические производные
JP2018510202A5 (cg-RX-API-DMAC7.html)
RU2017133660A (ru) Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
JP2021513543A5 (cg-RX-API-DMAC7.html)
PE20230182A1 (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter
CR20230218A (es) Nuevos derivados de indazol acetileno
PY2167570A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
FI934045A0 (fi) Pyridin- och imidazolderivat foer kardiovaskulaera sjukdomar
JP2021503451A5 (cg-RX-API-DMAC7.html)
AR128917A1 (es) Inhibidores de malt-1 de tiazolo[5,4-b]piridina
RU2023128311A (ru) Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение
JPWO2021132311A5 (cg-RX-API-DMAC7.html)
ME00057B (me) Novi derivati morfolina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže